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during radiation therapy.
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mate intraprostatic fiducial
marker positions on 2-
dimensional portal images.
Estimated positions were
compared with the actual
portal-imaged marker posi-
tions. The Clarity system
monitored intrafraction mo-
tion with an accuracy of
0.6 mm, which is compara-
ble with other motion-
monitoring systems used in
radiation therapy.were analyzed. To investigate the influence of intraprostatic markers and image quality
on ultrasound motion estimation, 3 observers rated image quality, and the marker vis-
ibility on ultrasound images was assessed.
Results: The median difference between Clarity-defined intrafraction marker loca-
tions and portal-imaged marker locations was 0.6 mm (with 95% limit of agreement
at 2.5 mm). Markers were identified on ultrasound in only 3 of a possible 240 in-
stances. No linear relationship between image quality and Clarity motion estimation
confidence was identified. The difference between Clarity-based motion estimates
and electronic portaleimaged marker location was also independent of image quality.
Clarity estimation confidence was degraded in a single fraction owing to poor probe
placement.
Conclusions: The accuracy of Clarity intrafraction prostate motion estimation is com-
parable with that of other motion-monitoring systems in radiation therapy. The effect
of fiducial markers in the study was deemed negligible as they were rarely visible on
ultrasound images compared with intrinsic anatomic features. Clarity motion estima-
tion confidence was robust to variations in image quality and the number of
ultrasound-imaged anatomic features; however, it was degraded as a result of poor
probe placement.  2018 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Prostate cancer radiation therapy (RT) is effective at
achieving long-term control of the tumor but at the expense
of potential side effects in surrounding organs at risk, such
as the rectum (1). Moderate and extreme hypofractionation
regimens have been studied to optimize therapeutic
response while minimizing toxicity in normal tissue (2, 3).
The efficacy of moderate hypofractionated prostate RT has
been demonstrated in recent trials, with growing evidence
of the effectiveness of more extreme hypofractionation
delivered using stereotactic body radiation therapy (SBRT),
leading to rapid adoption of prostate SBRT in a number of
countries (2, 4, 5). The implications of intrafraction motion
increase with hypofractionation, and hence there is growing
interest in intrafraction motion monitoring.
SBRT typically uses 5 fractions, with small planning
target volume (PTV) margins between 2 and 5 mm. The
magnitude of intrafraction motion as a percentage of
treatment time was shown to be up to 14% for displace-
ments > 3 mm and up to 3% for displacements > 5 mm,
with displacements > 10 mm observed in patients under-
going intensity modulated radiation therapy (IMRT) (6-
9). Prostate motion has been characterized previously as a
stochastic process, such as a random walk, where positional
variance increases over time (8). The motion is largely
attributed to transitory gas and filling of the rectum, but
bladder filling and femoral head rotation can also
contribute. Regular enemas and bladder-filling protocols
are routinely used during RT to assist consistent patient
setup and reduce motion, but these alone cannot achieve the
accuracy necessary for SBRT (10).
Potentially suitable systems have been developed to
monitor prostate position throughout treatment. CyberKnife(Accuray, Sunnyvale, CA) tracks radiopaque intraprostatic
fiducial markers 3-dimensionally using stereoscopic kilo-
voltage x-ray imaging (11, 12). The kilovoltage intra-
fraction monitoring (KIM) system estimates 3-dimensional
(3D) prostate motion by imaging implanted fiducial
markers using a standard C-arm linear accelerator (linac)
kilovoltage imager (13, 14). Calypso (Varian Medical
Systems, Palo Alto, CA) and RayPilot (Micropos, Goth-
enburg, Sweden) use electromagnetic transponders inde-
pendent of treatment platform. Calypso transponders are
implanted instead of fiducial markers, and an external
receiver detects their position at a rate of 25 Hz (15, 16).
RayPilot incorporates a single catheter-based transponder,
deployed via the urethra to the prostate, with a 30-Hz up-
date frequency (17, 18). Other systems, such as the MRI-
dian (ViewRay, Bedford, OH) and MR-linac (Elekta,
Stockholm, Sweden) integrate magnetic resonance imaging
with RT systems to facilitate adaptive treatment and motion
management (19, 20).
The Elekta Clarity Autoscan system uses transperineal
ultrasound (TPUS) without relying on fiducial markers or
extensive hardware installation. Ultrasound (US) imaging
has shown promise for patient setup verification and
interfraction motion management (9). The modality is
particularly suited to prostate RT in which the clinical
treatment volume (CTV) is unobstructed by bone or air and
moves relative to bony anatomy (21). The Clarity system
could improve care for patients in 2 key ways: First,
avoiding the risks, discomfort, and inconvenience of fidu-
cial insertion would be beneficial to patients and health care
economies. Second, the Clarity system is one of the few
systems that can monitor intrafraction motion of the pros-
tate on a conventional C-arm linac. Prostate motion during
the course of 1 fraction can be enough to result in
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immediately prior to “beam on” (6, 22). The clinical im-
plications of any motion become increasingly apparent as
we move toward extreme hypofractionation. A noninvasive,
accurate method of intrafraction motion monitoring would
improve the accuracy of delivery, reducing the chance of
treatment failure owing to geographic miss.
The high accuracy of Autoscan has been demonstrated
in vitro (23, 24). Lachaine and Falco (23) reported a mean
error  0.2 mm and standard deviation  0.4 mm for
an anthropomorphic pelvic phantom moving with an
amplitude  20 mm. Fast et al (24) implemented dynamic
multileaf collimator (dMLC) tracking guided by the Clarity
system. A root-mean-square error of 0.7 mmwas reported for
3DAutoscanmonitoring of amoving quality control phantom
using prostate motion traces.
The purpose of this study was to perform an in vivo
validation of Autoscan in patients receiving IMRT for
prostate cancer. Performance regarding intrafraction motion
estimation was evaluated by comparing Clarity-measured
prostate motion with prostate motion determined using
implanted fiducial markers and electronic portal imaging
(EPI).Methods and Materials
Clarity study
This study was conducted as part of the Clarity-Pro clinical
trial (NCT02388308). Prostatectomy patients were ineli-
gible for the trial. Patients consented to undergo TPUS at
treatment preparation, at verification, and during radiation
delivery. The study was approved by the Surrey and SE
Coast Regional Ethics Committee in the United Kingdom.Treatment preparation
Three cylindrical intraprostatic gold markers (FlexiMarc;
Cortex Manufacturing, Lake Stevens, WA), 1 mm in diam-
eter and 3mm in length, were implanted under transrectal US
guidance in all patients at least 1 week before simulation
(SIM) computed tomography (CT). Patients received a CT
scan (Brilliance Big Bore; Philips, Amsterdam, The
Netherlands) and 3D TPUS SIM scan while positioned using
the Clarity Autoscan probe kit incorporating knee rests and a
TPUS probe fixed to the couch by a baseplate. Probe posi-
tioning and imaging were optimized by manually reviewing
live B-mode US images prior to CT. Ideally, the prostate
appeared centrally in the US volume, with the bladder,
rectum, penile bulb, and pubic symphysis also visible. Probe-
and baseplate-indexed positions were recorded to aid
reproducible setup on treatment. The CT acquisition pa-
rameters were 140 kV, slice thickness of 1.5 mm, and pixel
size of 1 mm. Both the CTand treatment rooms incorporated
a ceiling-mounted infrared camera to track the probe in roomcoordinates, enabling US volume registration to the iso-
center. SIM was acquired immediately prior to CT.
Adhering to local clinical practice, we followed bladder-
filling and rectal-clearing protocols to mitigate anatomic
variation during treatment. Patients drank 350 mL of water
1 hour prior to SIM and treatment. Patients underwent
enemas 2 consecutive days before SIM, 1 hour prior to CT,
2 consecutive days before treatment, and for the first 10
treatment days. Rectal filling was measured on CT SIM.
Two patients with a rectal diameter > 4 cm from anterior to
posterior and 3.5 cm from left to right were scheduled for a
rescan, including SIM, after 2 days of additional enemas.
Five- or three-field step-and-shoot IMRT plans were
devised in ADAC Pinnacle (Philips) for the Elekta Synergy
linac with Agility multileaf collimator (MLC), delivering
60 Gy in 20 fractions or 74 Gy in 37 fractions (25, 26).
Three shrinking PTV margins from 6 mm to 0 mm,
incorporating seminal vesicles as clinically indicated, were
used (24). The CT image, treatment contours (CTV, rectum,
bladder, and penile bulb), and plan were imported into
Clarity Automated Fusion and Contouring software where
SIM and CT scans were registered. A reference positioning
volume (RPV) was contoured on SIM within the CTV to
define a reference template for Autoscan motion estimation
during treatment, the template being the RPV grown by
2 mm (23).Treatment and imaging
The patient was set up on the treatment couch with tattoo
markers aligned to room lasers. Live TPUS images were
compared with SIM to assist with probe positioning.
Prostate position and requisite couch moves were
determined on treatment by matching cone beam computed
tomography (CBCT) to planning CT using a mask regis-
tration incorporating the prostate and markers (XVI;
Elekta). Figure 1 a depicts the treatment imaging workflow.
A single 3D ultrasound (Guide) scan was acquired in
approximately 3 seconds at the start of the 60-second
CBCT acquisition. During CBCT acquisition and registra-
tion, a copy of the RPV contour, called the guidance
positioning volume (GPV), was manually registered on
Guide to match the SIM prostate position. Autoscan
monitoring was started prior to couch movement, and
intrafraction motion estimation data were continuously
acquired until treatment ended.
Monitoring has been described previously by Lachaine
and Falco (23) and O’Shea et al (27). Autoscan continuously
and automatically acquires 3D image data. A GPV template
is defined on the first monitoring image and compared with
all subsequent frames using intensity-based cross correla-
tion. Motion estimates incorporate translation and rotation
and are updated at a rate of approximately 3 Hz, depending
on acquisition parameters. An associated estimation confi-
dence factor (C) is generated by a proprietary algorithm (28).
A number of parameters are used to calculate C, including
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Fig. 1. a, Imaging workflow timeline for a typical 5-field intensity modulated radiation therapy fraction. b, Three-step
image processing workflow depicting (1) manual marker localizations, (2) Autoscan-based localization, and (3) projection
and comparison of marker centers of mass (CoM). CBCT Z cone beam computed tomography; EPI Z electronic portal
imaging; 2D Z 2-dimensional; 3D Z 3-dimensional.
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tween the GPV template and a region 1 mm from the search
location, and the minimum and maximum correlation scores
for subregions within the GPV. Cine-mode EPI images
(iView; Elekta) were acquired. The EPI panel detection area
was 41  41 cm, comprising 1024  1024 pixels. Image
pixel size was 0.25 mm at the isocenter.Comparison of Autoscan- versus marker-measured
motion
Prostate motion estimates were calculated by identifying
the initial 3D marker positions and applying translations
recorded by Autoscan. The Autoscan-predicted marker
positions were projected along the treatment beam path
onto the 2-dimensional (2D) EPI plane and compared with
the actual location of portal-imaged markers. Image pro-
cessing and analysis are illustrated in 3 steps (Fig. 1 b).
Step 1: Prostate localization using CBCT and
portal images
Three observers manually identified fiducial marker posi-
tions on the CBCT and subsequent cine portal images. To
facilitate marker discrimination, portal images were
contrast enhanced using a Laplacian of Gaussian filter with
a 3.5-mm kernel (SD, 1.0 mm) (29). Only the first cine
image from the first segment of each beam was analyzed
because markers tended to be obstructed by MLCs in
subsequent segments. To maintain accuracy, EPI images
with only 1 identifiable marker were excluded, as weremarker localizations with an interobserver error > 1.5 mm.
If only 1 marker was obscured by bony anatomy, its portal-
imaged location was estimated from its position relative to
the other markers on the CBCT scan.
Step 2: Autoscan-based prostate localization
The time stamps, prostate motion (translation and rotation)
estimates in room coordinates, and C values were extracted
from Autoscan data log files. To identify couch motion,
treatment beam activation, and associated time stamps,
linac logs were analyzed. Synchronization between Auto-
scan and linac was achieved by identifying couch motion
timings in both logs. EPI acquisition times were synchro-
nized to the linac by identifying beam-on time stamps. For
a given beam, the US-monitored estimate of 3D prostate
displacement was identified at the time of the first segment.
The initial CBCT marker positions were then shifted by this
estimate.
Step 3: Comparison between Autoscan and EPI fiducial
markerebased prostate motion estimates
The 3D Autoscan estimates of marker position were pro-
jected onto the 2D EPI plane for a given beam. Clinically,
prostate rotation is incorporated into the Autoscan GPV
center-of-mass (CoM) estimates but not displayed to the
operator. The GPV CoM could not be accurately identified
on CBCT or EPI images, owing to US-CBCT co-registra-
tion uncertainties. Instead, the projected markers’ CoM was
compared with the CoM of the portal-imaged markers, and
GPV rotation was disregarded. Monitoring error (E) was
quantified as the difference between the markers’ projected
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axes (u axis and v axis, respectively).
EPI panel flex < 2 mm with gantry angle may affect the
position of features on portal images (30). Flex-induced
shifts on each portal image were measured and a rigid 2D
correction applied. The MLC geometry for each field was
identified from the IMRT plan and used to create a template
for each portal image. Flex correction was then applied
through a correlation-based template match to the portal
image. A gray-level threshold was applied to each portal
image to enhance beam edge contrast prior to cross
correlation.
Precision of fiducial marker localization
A phantom study quantified the uncertainty associated with
marker localization in the EPI plane. Three fiducial markers
were mounted in the treatment field on a radiolucent holder
attached to a motion platform. A CBCT scan established
initial marker positions. Portal images were acquired for a
5-field IMRT sequence. The platform was moved between
fields, approximating the magnitude of intrafraction pros-
tate motion (up to 5 mm in all directions). Resulting portal
image marker CoM measurements were compared with the
projected CoM derived from shifting the initial CBCT
marker positions by the programmed motion. The experi-
ment was repeated 6 times, with repositioning of the gantry
and imaging panels to emulate typical interfraction varia-
tion. The median 2D error ð ~EphanÞ and 95% limit of
agreement (LOA) were calculated for a total of 30 images
across all 6 fractions.
Influence of fiducial markers and image quality on
Autoscan motion estimation
To assess the influence of the presence of fiducial markers
and image quality (IQ) on Autoscan performance, 3 ob-
servers (2 physicists and 1 therapist) reviewed all Guide
and CBCT images analyzed for this study using Clarity
Automated Fusion and Contouring software.
US IQ within a contour grown 2 mm from the GPV was
assessed on a 4-point scale using the following criteria: 1,
poor, with no discernible features and no prostate bound-
ary; 2, few features and partial boundary; 3, features and
partial boundary; and 4, many features and clear boundary.
The number of discernible features (N) was categorized as
either 5, >5 but <10, or 10.
The 3 most prominent US features within each GPV
were identified. Fiducial marker positions were also located
on CBCT images. Feature and fiducial marker locations
were compared. Figure 2 illustrates features visible on both
CBCT and TPUS images for 3 typical patients with mean
monitoring confidence values between 0.89 and 0.94. A US
image feature was deemed to be a fiducial marker if it was
identified by all 3 observers to  3 mm of the mean marker
position identified on the registered CBCT image.Observers reviewed Guide and CBCT images in separate
sessions to blind them to the feature positions when iden-
tifying marker positions.
Data analysis
Error distributions were tested for normality using a
1-sample, nonparametric Kolmogorov-Smirnov test. Bland-
Altman plots with nonparametric 95% LOAs were used to
assess the agreement between EPI-based and Autoscan-
based prostate motion (31). Autoscan monitoring confidence
(C) exhibited a range of C  0 but 1, warning the user if C
was <0.5 so that the user could pause treatment and repo-
sition the patient. The relationship between C and E was
investigated using linear regression. Linear regression was
also used to investigate whether GPV rotation was associated
with E.
Guide images were divided into 2 groups, marker pos-
itive and marker negative, based on whether markers were
identifiable on US images. To ascertain whether markers
influenced monitoring performance, mean C and E per
fraction (Cf and Ef, respectively) were calculated and their
medians ( ~Cf and ~Ef , respectively) recorded for each group.
Guide images were also classified according to their
IQ and categorization of the number of discernible
features (N). The distributions of Cf and Ef in each
category were examined to determine whether moni-
toring performance changed with either IQ or N. Box
plots of Cf and Ef were calculated for each category.
Kruskal-Wallis 1-way analysis of variance (ANOVA)
tests were also used to ascertain whether distributions in
each category were statistically different from each
other. All image processing and statistical analysis were
performed in MATLAB (2016a release; The MathWorks,
Natick, MA).
Results
Patient data
A total of 352 portal images (the first from each field) and
corresponding Autoscan data from 80 fractions were
analyzed across 16 patients. Of these portal images, 17
were excluded owing to large interobserver variation of
marker localizations. Intrafraction motion estimates
throughout 1 fraction were consistently below the Clarity-
defined threshold of C < 0.5 and also excluded. This left
330 fields with usable data.
Comparison of Autoscan- versus marker-measured
motion
Errors were nonnormally distributed in the vertical v-axis
(P Z .108 for u axis, P Z .038 for v axis). Table 1 shows
25%, 50%, 75%, and 95% LOAs. The median horizontal u-
axis error was ~Eu Z 0:0 mm (95% LOAs, 2.0 to
Fig. 2. a, Sagittal cone beam computed tomography image with associated transperineal ultrasound image depicting
prostate guidance positioning volume contour (blue) and fiducial marker identified visually (green arrow). b, c, Guidance
positioning volume features visible on transperineal ultrasound images but not cone beam computed tomography images.
High-intensity (white) ultrasound features seen in the central region of the prostate likely are calcifications. Ultrasound
features are also observed near the urethra and bladder-prostate interface. (A color version of this figure is available at www.
redjournal.org.)
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LOAs, e2.5 to 1.9 mm). For both the u and v axes, the
median absolute error was 0.6 mm. The median 2D error
vector magnitude was ~Eðu;vÞ Z 1:0 mm (2.6 mm). Bland-Altman plots in Figure 3 show the distribution of errors (E).
From the phantom study, the median experimental error
measured ~Eplan Z 0:8 mm (95% LOA, 1.1 mm) for 30
measurements over 6 simulated fractions.
Table 1 Limits of agreement for monitoring errors (E)
depicted in Figure 3 (Bland-Altman plot)
Limit of
agreement u-Axis, mm v-Axis, mm 2D magnitude, mm
25% 0.2 to 0.3 0.2 to 0.4 0.6
50% 0.5 to 0.6 0.5 to 0.7 1.0
75% 0.9 to 1.0 1.1 to 1.1 1.5
95% 2.0 to 2.1 2.5 to 1.9 2.6

 ~E

 0.6 0.6 1.0
Abbreviation: 2D Z 2-dimensional.
The median absolute error,

 ~E

, is 0.6 mm for both axes and 1.0 mm
for the 2D magnitude.
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(available online at www.redjournal.org). Proprietary
monitoring confidence (C) relative to E showed no linear
relationship between these quantities (R2 Z 0.03) or be-
tween the GPV motion or rotation and C (R2  0.11) or E
(R2  0.06).
Influence of fiducial markers, features, and IQ on
Clarity Autoscan motion estimation
Table 2 lists the number of markers identified by each
observer per fraction and per patient. Only 3 of a possible
240 markers were unanimously identified. This consensus
was achieved in only 2 fractions from 1 patient. Multiple
US image features were consistently identified within the
Guide GPV, including the 2 marker-positive fractions with
N > 5 but < 10.
Kruskal-Wallis ANOVA tests indicated no statistically
significant difference between the Cf distributions across IQ
scores. Likewise, Cf distributions were statistically indis-
tinguishable across the different N categories. Even so,
median Cf consistently improved with increasing IQ score
and N. No statistically significant difference was found
between the Ef distributions across IQ scores. Median Ef
also consistently improved with increasing IQ score and N.
Box plots and full ANOVA results are given in Figure E2
(available online at www.redjournal.org). Additional anal-
ysis of error distributions relative to the left-right, anterior-
posterior and superior-inferior patient axes are provided in
Appendix E1 (available online at www.redjournal.org).
Discussion
The median absolute difference between Autoscan-
predicted and portal-imaged prostate marker positions
was 0.6 mm, with 95% of differences  2.5 mm in the EPI
u and v axes scaled to the isocenter. This finding is in
agreement with a previous conference contribution that
reported a mean difference between EPI and Clarity of
1.2 mm (SD, 1.0 mm) across 4 patients (32). Our study
found similar agreement to that demonstrated for other
motion-monitoring systems validated in vivo usingradiographic imaging. RayPilot intrafraction prostate mo-
tion was approximated by moving the transponder inside
the prostatic urethra. The mean and maximum 3D errors
were 1.7 mm (SD, 1.0 mm) and 4.6 mm, respectively (18).
Only Calypso interfraction motion estimation validations
have been reported (16, 33). Willoughby et al (16) reported
mean and maximum 3D errors of 1.5 mm (SD, 1.1 mm) and
3.8 mm, respectively, over 44 fractions in 11 patients.
Ogunleye et al (33) found mean differences of 1.2 mm (SD,
0.9 mm), 1.1 mm (SD, 0.9 mm), and 0.7 mm (SD, 0.5 mm)
in the anterior-posterior, superior-inferior, and left-right
directions, respectively. Foster et al (34) found mean dif-
ferences of e0.81 mm (95% LOAs, 2.83 to 2.67 mm),
e0.41 mm (95% LOAs, 3.41 to 2.59 mm), and 0.06 mm
(95% LOAs, 1.97 to 2.09 mm) for the anterior-posterior,
superior-inferior, and left-right directions, respectively,
over 250 fractions.
The KIM system was evaluated in vitro, finding a mean
positional error over 6 prostate-derived motion traces of
0.6 mm (SD, 0.4 mm) for left-right, 0.2 mm (SD, 0.1 mm)
for superior-inferior, and 0.4 mm (SD, 0.4 mm) for
anterior-posterior (35). KIM has not been compared with
any other 4-dimensional localization technique in vivo.
We propose that in a prostate SBRT setting, both Clarity
and CBCT will be used. CBCT will be used for daily
interfraction adaptation. Clarity Autoscan will measure
intrafraction motion for use with dMLC tracking or gating,
which has been shown to improve target dose coverage (24,
36). Several comparable motion compensation methods
have been shown to reduce planned therapy g-failure rates
for a sample of representative prostate motions from 17.3%
to 1.4% (37, 38). The feasibility of using Clarity with
dMLC tracking has been previously described by Fast et al
(24) with a similar dosimetric advantage to other methods.
Owing to their similar accuracy, recommendations for
margin reduction using Calypso may be applied to Clarity.
Tanyi et al (39) used Calypso with a gating threshold of
4 mm for shifts > 1 second, calculating a reduced PTV
margin of 1.4 mm, 2.3 mm, and 2.6 mm (left-right,
anterior-posterior, and superior-inferior, respectively) using
the methodology of van Herk et al (40). Keall et al (15)
reported dMLC tracking using Calypso in vivo for pros-
tate SBRT. PTV margins were not changed, however, and
the authors advised caution when considering margin
reduction until further clinical data are collected.
Clinically, poor IQ can arise from inadequate probe
placement; shadowing of features obstructed by bony anat-
omy, such as the pubic symphysis; or attenuation from excess
subcutaneous perineal tissue. This may limit Autoscan con-
fidence and degrademonitoring accuracy. In this study, only a
single fraction exhibited confidence factors consistently
below the Clarity alert threshold, C< 0.5, owing to a poorly
positioned probe. Poor confidence scores were avoided by
following an imaging protocol to ensure consistent patient
setup relative to SIM, checking that the field of view fully
encompassed the GPV with the prostate centered. RT radi-
ographers were trained to optimize these setup parameters in
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80 exhibited a low monitoring confidence, where it was
deemed the protocol was not adequately followed.
This study found no relationship between monitoring
performance (Cf, Ef) and IQ (IQ score, N). However, a pre-
fraction monitoring session to manually inspect the Auto-
scan confidence factor may be used to ensure that C is >0.5
to avoid suspending treatment. No patients in this studyexhibited consistently poor motion estimates across all
fractions; however, the aforementioned preselection step
could also be implemented at SIM to ensure the patient is
eligible for Autoscan use.
Some experimental limitations of the study were identi-
fied. The 3 largest monitoring errors in figure 3c
[E  4.1 mm] were attributable to the position uncertainty
arising from different Guide and CBCTacquisition times and
Table 2 Number of markers identified on ultrasound images by observers, with N and IQ per fraction and median Cf and Ef for
markereidentifiable (positive) and markereunidentifiable (negative) groups
Observer 1 Observer 2 Observer 3 All observers
Marker
positive
Marker
negative
Marker
positive
Marker
negative
Marker
positive
Marker
negative
Marker
positive
Marker
negative
Fiducial markers 8 232 3 237 9 231 3 237
Fractions 6 74 2 78 7 73 2 78
Patients 3 14 1 16 4 13 1 16
N
5 1 16 0 12 3 45 0 18
>5 but <10 3 24 2 16 4 28 2 32
10 2 34 0 40 0 0 0 28
IQ score
1 0 2 0 0 0 0 0 0
2 1 19 0 23 1 28 0 23
3 5 35 1 26 6 29 2 37
4 0 18 1 29 0 16 0 18
Confidence (median Cf) 0.90 0.87 0.84 0.87 0.87 0.87 0.84 0.87
Error (median Ef), mm 0.69 1.02 0.69 1.02 0.84 1.07 0.69 1.02
Abbreviations: Cf Z confidence factor per fraction; Ef Z monitoring error per fraction; IQ Z image quality; N Z number of discernible features.
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EPI acquisition. TheGuide scan typically lasted< 3 seconds,
recorded at the start of the 60-second CBCT acquisition.
Once completed, the RPVwas manually positioned in Guide
as a reference for the subsequent monitoring session (GPV).
This did not account for prostate motion during most of the
CBCT scan, which has been identified as a source of error in
previous studies comparing Calypso with CBCT (34). The 2
largest monitoring errors where E(u, v) was >5 mm were
attributable to motion during CBCT. This was verified by
manually registering CBCT and Guide images, indicating a
prostate shift of 6 mm. As this magnitude of motion was
rarely observed and it risked introducing greater errors,
manual registration was not conducted.
Monitoring traces were synchronized to beam event
messages in the linac log in lieu of an EPI acquisition time
stamp. This indirect synchronization between monitoring
and portal imaging could have produced further uncer-
tainty, which could not be quantified; however, an 8-mm
anterior prostate displacement was observed immediately
after a segment with an error E(u, v) Z 4.1 mm.
Interobserver variation of marker localizations was iden-
tified as a potential source of error, particularly on CBCT,
where spatial resolution is poor (34). This was mitigated by
excluding localizations with variation > 1.5 mm. Disregard-
ing prostate rotation was another potential source of error;
however, rotations are not provided to the operator during
clinical use, and no relationship between rotation and E was
identified.
Monitoring confidence improves with US image feature
density (28). Intrinsic anatomic features were more
frequently observed than implanted fiducial markers on
TPUS images. Markers were discernible for only 2 frac-
tions, in which the average number of features was high:
N > 5 but < 10 (Fig. 2). As a result, fiducial markers werenot considered to significantly influence Autoscan confi-
dence (C).
Conclusions
The Clarity system can monitor intrafraction prostate mo-
tion with an accuracy in the 2D EPI frame of reference of
0.6 mm (median absolute monitoring error), with 95%
LOAs between 2.5 and 2.1 mm, which is comparable
with other motion-monitoring systems used in RT. Auto-
scan motion estimation confidence was not reliant on the
presence of intraprostatic markers, and no significant
relationship between estimation confidence and IQ was
observed.
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